Efficacy and Safety of Oral Treprostinil Monotherapy for the Treatment of Pulmonary Arterial Hypertension: A Randomized, Controlled Trial
暂无分享,去创建一个
Z. Jing | A. Torbicki | Kaifeng Xu | L. Rubin | T. Pulido | R. White | R. Allen | C. Jerjes-Sánchez | K. Parikh | C. Arneson | K. Laliberte | D. Yehle
[1] R. Benza,et al. Rapid Transition from Inhaled Iloprost to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension , 2013, Cardiovascular therapeutics.
[2] D. Badesch,et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. , 2012, Chest.
[3] R. Voswinckel,et al. Inhaled treprostinil: a therapeutic review , 2012, Drug design, development and therapy.
[4] W. Seeger,et al. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[5] M. Humbert,et al. Survival of Chinese patients with pulmonary arterial hypertension in the modern treatment era. , 2011, Chest.
[6] Z. Jing,et al. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. , 2011, American journal of respiratory and critical care medicine.
[7] Z. Jing,et al. [The efficacy and safety of bosentan therapy for Chinese patients with idiopathic pulmonary arterial hypertension: an open-label, prospective multicenter study]. , 2011, Zhonghua xin xue guan bing za zhi.
[8] J. Dingemanse,et al. Lack of a Pharmacokinetic Interaction Between Oral Treprostinil and Bosentan in Healthy Adult Volunteers , 2010, Journal of clinical pharmacology.
[9] Horst Olschewski,et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. , 2010, Journal of the American College of Cardiology.
[10] L. Shapiro,et al. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[11] B. Brundage,et al. Tadalafil Therapy for Pulmonary Arterial Hypertension , 2009, Circulation.
[12] K. Gotzkowsky,et al. Overview of the Drug-Drug Interaction Potential with Treprostinil. , 2009, ATS 2009.
[13] V. Tapson,et al. Sustained Plasma Concentrations of Treprostinil Following Chronic Dosing in Patients with Pulmonary Arterial Hypertension (PAH). , 2009, ATS 2009.
[14] B. Casserly,et al. Ambrisentan for the treatment of pulmonary arterial hypertension , 2008, Drug design, development and therapy.
[15] B. Wiens,et al. Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2 , 2008, Circulation.
[16] R. Benza,et al. Dose Proportionality of Treprostinil Sodium Administered by Continuous Subcutaneous and Intravenous Infusion , 2008, Journal of clinical pharmacology.
[17] Z. Jing,et al. Registry and survival study in chinese patients with idiopathic and familial pulmonary arterial hypertension. , 2007, Chest.
[18] R. Barst,et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. , 2006, American journal of respiratory and critical care medicine.
[19] C. Ricachinevsky,et al. Treatment of pulmonary arterial hypertension. , 2006, Jornal de pediatria.
[20] W. Seeger,et al. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. , 2006, Journal of the American College of Cardiology.
[21] R. Barst,et al. Delivery of intravenous treprostinil at low infusion rates using a miniaturized infusion pump in patients with pulmonary arterial hypertension , 2006, The journal of vascular access.
[22] T. Fleming,et al. Sildenafil citrate therapy for pulmonary arterial hypertension. , 2005, The New England journal of medicine.
[23] R. Barst,et al. Prostanoid therapy for pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.
[24] M. Humbert,et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.
[25] K. Wasserman,et al. Beraprost therapy for pulmonary arterial hypertension. , 2003, Journal of the American College of Cardiology.
[26] S. Rich,et al. Efficacy and Safety of Treprostinil: An Epoprostenol Analog for Primary Pulmonary Hypertension , 2003, Journal of cardiovascular pharmacology.
[27] W. Seeger,et al. Inhaled iloprost for severe pulmonary hypertension. , 2002, The New England journal of medicine.
[28] M. Humbert,et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. , 2002, Journal of the American College of Cardiology.
[29] S. Rich,et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. , 2002, American journal of respiratory and critical care medicine.
[30] L. Rubin,et al. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. , 2002, American journal of respiratory cell and molecular biology.
[31] 马建新,et al. 用FEV6.0代替FVC诊断气道阻塞和肺功能受限[英]/Swanney MP…∥Am J Respir Crit Care Med. , 2002 .
[32] Avid,et al. BOSENTAN THERAPY FOR PULMONARY ARTERIAL HYPERTENSION , 2002 .
[33] Inda,et al. A COMPARISON OF CONTINUOUS INTRAVENOUS EPOPROSTENOL ( PROSTACYCLIN ) WITH CONVENTIONAL THERAPY FOR PRIMARY PULMONARY HYPERTENSION , 2000 .
[34] W. Seeger,et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. , 1999, American journal of respiratory and critical care medicine.
[35] B. Groves,et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.
[36] B. Groves,et al. Prostacyclin‐induced Acute Pulmonary Vasodilation in Primary Pulmonary Hypertension , 1982, Circulation.